Extended Data Fig. 2: JBJ-09-063 efficacy is reduced in vitro unless combined with gefitinib in H3255GR and DFCI52 cells or with osimertinib in H3255GR-C797S and DFCI52-C797S cells.
a, Cell viability and b, Western blot analyses of H3255GR cells treated with indicated concentrations of osimertinib, JBJ-09-063 and JBJ-04-125-02. c, Cell viability, d, apoptosis and e, Western Blot analyses of DFCI52 cells treated with indicated concentrations of gefitinib, JBJ-09-063 or the combination of both agents. Cell viability of H3255GR-C797S cells in panel f, and DFIC52-C797S cells in panel g treated with indicated concentrations of JBJ-09-063 and osimertinib as a single agent or in combination of both compounds. h, Western Blot analyses of H3255GR-C797S and DFIC52-C797S cells treated with indicated concentrations of JBJ-09-063 and osimertinib as a single agent or in combination of both compounds. All cell viability assays shown in this figure were graphed as a percentage of activity relative to DMSO control (mean ± SD) over indicated concentrations. Data shown in panels a, c, f, g are representative figures from N=3 independent experiments with 3 technical replicates in each experiment. The apoptosis experiments were graphed as normalized caspase-3/7 activity (in average arbitrary units ± SEM)) over time. Data shown in panel f is a representative figure from N=3 independent experiments with 12 technical replicates in each experiment.
